Integra LifeSciences Holdings (IART) - Total Liabilities
Based on the latest financial reports, Integra LifeSciences Holdings (IART) has total liabilities worth $2.61 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Integra LifeSciences Holdings cash flow conversion to assess how effectively this company generates cash.
Integra LifeSciences Holdings - Total Liabilities Trend (1995–2024)
This chart illustrates how Integra LifeSciences Holdings's total liabilities have evolved over time, based on quarterly financial data. Check Integra LifeSciences Holdings asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Integra LifeSciences Holdings Competitors by Total Liabilities
The table below lists competitors of Integra LifeSciences Holdings ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Omada Health, Inc. Common Stock
NASDAQ:OMDA
|
USA | $70.12 Million |
|
Sri Trang Agro-Industry Public Company Limited
BK:STA
|
Thailand | ฿41.47 Billion |
|
Ottogi
KO:007310
|
Korea | ₩1.41 Trillion |
|
GuangDong Rifeng Electric Cable Co Ltd
SHE:002953
|
China | CN¥1.67 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥130.20 Million |
|
Omeros Corporation
NASDAQ:OMER
|
USA | $406.18 Million |
|
Artis Real Estate Investment Trust
TO:AX-UN
|
Canada | CA$1.19 Billion |
|
Yijiahe Technology Co Ltd
SHG:603666
|
China | CN¥1.06 Billion |
Liability Composition Analysis (1995–2024)
This chart breaks down Integra LifeSciences Holdings's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Integra LifeSciences Holdings stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Integra LifeSciences Holdings's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Integra LifeSciences Holdings (1995–2024)
The table below shows the annual total liabilities of Integra LifeSciences Holdings from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.49 Billion | +13.58% |
| 2023-12-31 | $2.19 Billion | +5.21% |
| 2022-12-31 | $2.09 Billion | -0.58% |
| 2021-12-31 | $2.10 Billion | -0.13% |
| 2020-12-31 | $2.10 Billion | +11.33% |
| 2019-12-31 | $1.89 Billion | +8.91% |
| 2018-12-31 | $1.73 Billion | -22.98% |
| 2017-12-31 | $2.25 Billion | +132.26% |
| 2016-12-31 | $968.29 Million | -5.37% |
| 2015-12-31 | $1.02 Billion | +17.04% |
| 2014-12-31 | $874.30 Million | +66.20% |
| 2013-12-31 | $526.05 Million | -18.55% |
| 2012-12-31 | $645.82 Million | -0.87% |
| 2011-12-31 | $651.47 Million | +25.93% |
| 2010-12-31 | $517.35 Million | +4.47% |
| 2009-12-31 | $495.22 Million | -27.62% |
| 2008-12-31 | $684.23 Million | +22.71% |
| 2007-12-31 | $557.58 Million | +75.64% |
| 2006-12-31 | $317.46 Million | +100.14% |
| 2005-12-31 | $158.61 Million | +6.53% |
| 2004-12-31 | $148.89 Million | +3.40% |
| 2003-12-31 | $144.00 Million | +431.92% |
| 2002-12-31 | $27.07 Million | +15.04% |
| 2001-12-31 | $23.53 Million | -28.11% |
| 2000-12-31 | $32.73 Million | +15.66% |
| 1999-12-31 | $28.30 Million | +757.58% |
| 1998-12-31 | $3.30 Million | +26.92% |
| 1997-12-31 | $2.60 Million | +13.04% |
| 1996-12-31 | $2.30 Million | +15.00% |
| 1995-12-31 | $2.00 Million | -- |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural r… Read more